Abnormal bone marrow findings in patients following treatment with chimeric antigen receptor-T cell therapy

Background: Bone marrow (BM) assessment after CAR-T cell immunotherapy infusion is not routinely performed to monitor adverse events such as cytopenias, hemophagocytic lymphohistiocytosis, or infections. Our institution has performed BM biopsies as part of CAR-T cell treatment protocols, encompassing pre- and post-treatment time points and during long-term follow-up. Methods: We conducted a systematic retrospective review of BM abnormalities observed in samples from 259 patients following CAR-T cell immunotherapy. We correlated BM pathology findings with mortality, relapse/residual disease, and laboratory values. Results: At a median of 35.5 days post-CAR-T infusion, 25.5% showed severe marrow hypocellularity, and 6.2% showed serous atrophy, and peripheral blood cytopenias corroborated these observations. Marrow features associated with reduced disease burden post-CAR-T infusion include increased lymphocytes seen in 16 patients and an increase of macrophages or granulomatous response seen in 25 patients. However, a 100-day landmark analysis also showed increased marrow histiocytes were associated with lower survival (median OS 6.0 vs. 21.4 months, p =.026), as was grade 2-3 marrow reticulin (18 patients) (median OS 12.5 vs. 24.2 months, p =.034). Conclusions: These data represent the first systematic observations of BM changes in patients receiving CAR-T cell immunotherapy.

Automated summary

This study retrospectively observed bone marrow abnormalities in 259 patients receiving CAR-T cell immunotherapy. The study found that 25.5% of patients showed severe marrow hypocellularity and 6.2% showed serous atrophy at a median of 35.5 days post-infusion. Additionally, the study found correlations between bone marrow pathology findings and disease burden and survival rates.